一种结合cadonilimab和化疗的新治疗方法显示,早期胃癌效果显著,半数患者在治疗后未得任何可检测的癌症。 A new treatment combining cadonilimab and chemotherapy showed strong results in early-stage stomach cancer, with half of patients achieving no detectable cancer after treatment.

在2025年ESMO亚洲大会上介绍的第二阶段试验发现,将PD-1/CTLA-4双性抗体Cadonilimab(PD-1/CTLA-4双性抗体)与SOX化疗疗法相结合,作为可重新剖析的胃或胃道切入关口癌症的新发性治疗,导致28.6%的病理完整反应率上升至50%,每三个星期服一次剂量。 A Phase II trial presented at the 2025 ESMO Asia Congress found that combining cadonilimab, a PD-1/CTLA-4 bispecific antibody, with SOX chemotherapy as neoadjuvant treatment for resectable gastric or gastroesophageal junction cancer resulted in a 28.6% pathological complete response rate, rising to 50% with every-three-week dosing. 主要病理反应率总体为71.4%,在Q3W组中为85.7%,所有病人都进行了R0再切除和严重的肿瘤下降。 Major pathological response rates were 71.4% overall and 85.7% in the Q3W group, with all patients achieving R0 resection and significant tumor downstaging. 疗程显示一种可管理的安全情况。 The regimen showed a manageable safety profile. 第三阶段试验正在进行中,中国已核准对子宫颈癌进行高级胃癌治疗。 A Phase III trial is ongoing, and cadonilimab is already approved in China for advanced gastric cancer.